53 completed. 53 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 53 | Completed 53 |
| Phase 2 | 9 | Completed 9 |
Follow Enterobacteriaceae Infections: new trials by email Literature Review of Enterobacteriaceae Infections trials Research Report on Enterobacteriaceae Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ShigETEC Vaccine Study in Bangladesh ShigETEC live, attenuated, oral vaccine, Placebo - Healthy Volunteers | Phase 1 | Completed | Eveliqure Biotechnologies GmbH | 196 | 2023-11-26 | 2026-01-23 |
| Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults TYP04A Low Dose without Alum investigational vaccine, TYP04B Full Dose without Alum investigational vaccine, TYP03A Low Dose with Alum investigational vaccine - Typhoid Fever | Phase 1 | Completed | GlaxoSmithKline | 97 | 2022-11-28 | 2025-01-24 |
| Shigella CVD 31000: Study of Responses With Shigella-ETEC Vaccine Strain CVD 1208S-122 strain CVD 1208S-122, Placebo - Shigella Infection, Enterotoxigenic Escherichia Coli Infection | Phase 1 | Completed | University of Maryland, Baltimore | 53 | 2022-09-29 | 2026-02-02 |
| A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) low dose, Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) low dose, Typhoid conjugate vaccine (TCV) low dose - Salmonella Infections | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 155 | 2022-09-13 | 2025-11-28 |
| Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine 'Typhocon' in Bangladesh Typhoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT) - Typhoid | Phase 1 / Phase 2 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 630 | 2022-07-01 | 2024-12-24 |
| Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections GSK3882347, Nitrofurantoin, Placebo - Uncomplicated Urinary Tract Infections, Urinary Tract Infections | Phase 1 | Completed | GlaxoSmithKline | 140 | 2022-05-18 | 2026-03-13 |
| Controlled Human Infection Model Challenge/Rechallenge Shigella sonnei 53G, Shigella flexneri 2a 2457T - Shigellosis | Phase 1 | Completed | PATH | 46 | 2022-04-26 | 2025-01-31 |
| A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants AltSonflex1-2-3 High Dose, AltSonflex1-2-3 Medium Dose, AltSonflex1-2-3 Low Dose - Diarrhoea | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 551 | 2021-10-06 | 2026-06-22 |
| Phase 1 Trial for Safety, Tolerability, and Immunogenicity of a Live, Attenuated, Oral Shigella/ETEC Combination Vaccine to Healthy Adults ShigETEC live, attenuated, oral vaccine, Placebo - Diarrheal Disease, Infectious, Gastrointestinal Disease | Phase 1 | Completed | Eveliqure Biotechnologies GmbH | 84 | 2020-09-16 | 2022-06-08 |
| Study to Evaluate the Safety, Tolerability and Immunogenicity of a Potential Enteric Fever Vaccine ZH9PA and ZH9, Placebo, ZH9PA - Enteric Fever | Phase 1 | Completed | Prokarium Ltd | 46 | 2019-12-16 | 2025-08-17 |
| A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants Shigella 4V, MenACWY, Rabies - Shigellosis | Phase 1 / Phase 2 | Completed | LimmaTech Biologics AG | 597 | 2019-09-02 | 2026-06-23 |
| Dose Escalating Study of Intramuscular Invaplex[AR-DETOX] Invaplex[AR-DETOX], Placebo - Diarrhea | Phase 1 | Completed | PATH | 58 | 2019-03-18 | 2021-07-29 |
| Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults EuTCV, Typbar-TCV™, Typhim Vi® - Typhoid Fever | Phase 1 | Completed | EuBiologics Co.,Ltd | 75 | 2019-03-16 | 2019-12-09 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK, the Measure of How the Human Body Processes a Substance) of ETX0282 When Administered Orally to Healthy Participants ETX0282, Cefpodoxime proxetil, Placebo - Healthy Volunteers | Phase 1 | Completed | Entasis Therapeutics | 99 | 2018-03-16 | 2020-01-14 |
| Dose Escalating Study of a Prototype CS6 Subunit Vaccine With a Modified Heat-labile Enterotoxin From Enterotoxigenic Escherichia Coli (ETEC) CssBA, dmLT - Diarrhea | Phase 1 | Completed | PATH | 50 | 2018-01-16 | 2021-01-06 |
| Effects of Aging on Primary and Secondary Vaccine Responses Fluzone® quadrivalent, Fluzone High Dose, Fluad - Influenza, Hepatitis A | Phase 1 | Completed | Stanford University | 54 | 2017-09-19 | 2024-12-16 |
| Safety Study of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine - Dysentery, Dysentery, Bacillary | Phase 1 | Completed | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 180 | 2017-07-18 | 2018-10-17 |
| A Study to Evaluate Safety and Immunogenicity of 1 Booster Dose of 1790GAHB Vaccine in Healthy Adults Primed With 3 Doses of 1790GAHB Vaccine in Study H03_01TP Compared to 1 Vaccination of 1790GAHB in Either Subjects Who Received Placebo in the Same Study or naïve Subjects Not Part of H03_01TP Study GVGH Shigella sonnei 1790GAHB vaccine - Dysentery, Bacillary | Phase 1 | Completed | GlaxoSmithKline | 35 | 2017-03-16 | 2019-06-28 |
| Shigella WRSS1 Vaccine Trial in Bangladesh Shigella sonnei Strain WRSS1 Vaccine, Placebo - Diarrhea | Phase 1 | Completed | PATH | 16 | 2017-02-23 | 2020-03-31 |
| Efficacy of B7A BSIgG Against E. Coli Strain B7A Challenge Anti CS6 BSIgG product (Lot PD1601105CS), Anti B7A BSIgG product (Lot PD1601132ET), Bovine Immunoglobin Negative Control (Lot PD161071NC) - Healthy Volunteer | Phase 1 | Completed | Johns Hopkins Bloomberg School of Public Health | 60 | 2017-01-01 | 2019-06-14 |
Showing 20 of 53. Sign in to see all of them.
Dysentery, Bacillary (25) · Escherichia coli Infections (12) · Typhoid Fever (12) · Diarrhea (8) · Dysentery (4) · Urinary Tract Infections (4) · Plague (3) · Cholera (2) · Gastrointestinal Diseases (2) · Paratyphoid Fever (2) · Spinal Cord Injuries (2) · Arthritis, Reactive (1) · Bacterial Infections (1) · Digestive System Diseases (1)
Bacterial Infections and Mycoses (53) · Infections (53) · Bacterial Infections (52) · Gram-Negative Bacterial Infections (52) · Digestive System Diseases (26) · Gastroenteritis (25) · Intestinal Diseases (25) · Gastrointestinal Diseases (24) · Dysentery (21) · Salmonella Infections (12) · Pathological Conditions, Signs and Symptoms (9) · Signs and Symptoms (8) · Signs and Symptoms, Digestive (8) · Female Urogenital Diseases (4)
Vaccines (6) · Vi polysaccharide vaccine, typhoid (6) · Boostrix (3) · Adjuvants, Pharmaceutic (2) · Meningococcal Vaccines (2) · Adjuvants, Vaccine (1) · Albendazole (1) · Aluminum Hydroxide (1) · Arsenic (1) · Cefpodoxime Proxetil (1) · Ciprofloxacin (1) · Fluzone High-Dose (1) · Hepatitis A Vaccines (1) · Krebs-Ringer HEPES bicarbonate solution (1) · MenACWY (1)
National Institute of Allergy and Infectious Diseases (NIAID) (7) · PATH (7) · U.S. Army Medical Research and Development Command (6) · GlaxoSmithKline (5) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (3) · Eveliqure Biotechnologies GmbH (2) · GSK Vaccines Institute For Global Health S.r.l. (2) · International Centre for Diarrhoeal Disease Research, Bangladesh (2) · LimmaTech Biologics AG (2) · US Department of Veterans Affairs (2) · University of Maryland, Baltimore (2) · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (1) · DynPort Vaccine Company LLC, A GDIT Company (1) · Entasis Therapeutics (1) · EuBiologics Co.,Ltd (1)
United States (29) · Bangladesh (5) · Belgium (4) · United Kingdom (3) · France (2) · Israel (2) · Kenya (2) · Australia (1) · China (1) · Hungary (1) · Malawi (1) · Philippines (1) · Switzerland (1) · Thailand (1)
Barbara Trautner, MD (2) · Barbara W Trautner, MD (1) · Carl Mason, MD (1) · Christoph Hatz, Prof. Dr. (1) · Christopher Duplessis, MD, MPH, MS (1) · Clayton D Harro, MD, ScM (1) · Cornelia Dekker, MD (1) · David JM Lewis, MD (1) · David Tribble, MD, PhD (1) · Eric Sheldon, MD (1) · Farhana Khanam, MPhil, PhD (1) · Feng-Ying C Lin, M.D. (1)
PMID 27490698, PMID 28735965, PMID 34017343, PMID 10334980, PMID 10471979, PMID 1928194, PMID 20619378, PMID 21813209, PMID 21980445, PMID 24657719, PMID 25410205, PMID 26048203, PMID 26162850, PMID 2644914, PMID 26865592, PMID 27146000, PMID 27581434, PMID 29534721, PMID 29776750, PMID 3046725, PMID 30473185, PMID 31757774, PMID 31905228, PMID 33186516, PMID 33207794, PMID 33807097, PMID 33849723, PMID 34793505, PMID 35536001, PMID 37666695, PMID 38853614, PMID 39893179, PMID 40152601, PMID 41587557, PMID 41999631, PMID 42234814, PMID 597710, PMID 6363727
2016 (1), R01AI130398 (1)